Data from a Phase 1 trial is the latest bullish news from the biotech that may offer cheap entry to weight-loss mania.
Viking Therapeutics posts positive results for oral weight-loss drug. Analysts remain unanimous the stock’s a buy.
Read Next
- Rep. Ocasio-Cortez fundraising soars as she blasts Trump
- Meta CEO Zuckerberg considered spinning off Instagram 2018: FTC trial
- Trump eyes deporting U.S. citizens to foreign prisons
- Amazon emails sellers to gauge how Trump’s tariffs impacting business
- LSEG appoints Gianluca Biagini and Ron Lefferts as Co-Heads of Global Data & Analytics division
- Blackthorn Finance enters special administration
- What Are the Best Financial Goals for Couples?
